Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Brief Summary: This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to compare how well they work with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may find tumor cells and help kill them. It is not yet known whether temozolomide and radiation therapy are more effective when given together with or without bevacizumab in treating glioblastoma or gliosarcoma.


Options:
A: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
B: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide
D: Arm Label: Arm I (radiation therapy, temozolomide, placebo); Type: ACTIVE_COMPARATOR; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Temozolomide | Arm Label: Arm II (radiation therapy, temozolomide, bevacizumab); Type: EXPERIMENTAL; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Biological: Bevacizumab, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Temozolomide | Intervention Type: RADIATION; Name: 3-Dimensional Conformal Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: RADIATION; Name: Intensity-Modulated Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab)

Answer: D